Growth Hormone Peptides ·
Tesamorelin may help reduce abdominal obesity in HIV patients but shows limited cognitive benefits. This study investigates the effects of Tesamorelin on neurocognitive impairment (NCI) in individuals with HIV who are virally suppressed and experiencing abdominal obesity. Given the connection between abdominal obesity and cognitive decline, understanding Tesamorelin's potential impact is crucial for improving the quality of life in this population.
What this study examined
This phase 2 randomized open-label clinical trial focused on individuals with HIV who had achieved viral suppression through antiretroviral therapy and were also experiencing abdominal obesity, defined by elevated waist circumference. A total of 73 participants were enrolled and randomized in a 3:2 ratio to receive either Tesamorelin (2 mg subcutaneously daily) or standard of care (SOC). The primary outcome of the study was the change in neurocognitive performance after six months, while secondary outcomes included waist circumference, mood, and daily functioning. Participants with conditions other than HIV that could cause NCI, active substance use disorders, or malignancies were excluded from the study.
Why it matters for Tesamorelin research
The relationship between abdominal obesity and neurocognitive impairment in people living with HIV is an area of growing concern, as visceral adiposity and inflammation may contribute to cognitive decline. Tesamorelin, a growth hormone-releasing hormone, has been shown to reduce abdominal obesity and increase insulin-like growth factor 1 (IGF-1) levels. This study seeks to determine whether these effects translate into improved cognitive outcomes, providing insights into the potential therapeutic role of Tesamorelin for this vulnerable population.
Key findings
- The study included 73 participants with HIV, all virally suppressed and experiencing abdominal obesity.
- Participants were randomized to receive either Tesamorelin or standard of care for six months.
- The Tesamorelin group showed a trend toward improved neurocognitive performance, but the results were not statistically significant.
- Waist circumference decreased significantly in the Tesamorelin group compared to the standard of care group.
- IGF-1 levels increased in the Tesamorelin group, although this did not correlate with cognitive improvements.
- The study recognized limitations, including insufficient power and the absence of a placebo control.
How Tesamorelin works (background)
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone. This increase in growth hormone can lead to elevated levels of IGF-1, a hormone that plays a critical role in growth and metabolism. In the context of HIV, where abdominal obesity is prevalent, Tesamorelin's ability to reduce visceral fat may help mitigate some of the inflammatory processes associated with cognitive decline. While the precise mechanisms linking IGF-1 levels and neurocognitive function remain under investigation, it is hypothesized that improved metabolic health may contribute to better cognitive outcomes.
Practical takeaways for researchers
This study highlights the need for further research into the cognitive effects of Tesamorelin in populations with HIV and abdominal obesity. While the findings suggest a potential benefit in reducing waist circumference, the lack of significant cognitive improvement indicates that more extensive studies with larger sample sizes and control groups are necessary. Researchers should consider exploring the long-term effects of Tesamorelin on both metabolic and cognitive outcomes, as well as its interactions with other treatments for HIV.
FAQ
What is Tesamorelin used for?
Tesamorelin is primarily used to reduce abdominal fat in HIV-infected patients with lipodystrophy, but its effects on cognitive function are still being studied.
How does Tesamorelin affect IGF-1 levels?
Tesamorelin stimulates the release of growth hormone, which in turn increases levels of IGF-1, a hormone important for growth and metabolism.
Are there any side effects associated with Tesamorelin?
While Tesamorelin is generally well-tolerated, potential side effects can include injection site reactions, headache, and changes in glucose metabolism.
Source: PubMed · J Infect Dis · published 2025-06-02.